Browsing by Author "Malvasi, A. (15045047100)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Asymptomatic isthmico-cervical uterine perforation with IUD - Our experience and literature review(2016) ;Sparic, R. (23487159800) ;Dotlic, J. (6504769174) ;Mirkovic, L. (23474551800) ;Stamenkovic, J. (54414801300) ;Kotlica, B. Kastratovic (55580169300) ;Nejkovic, L. (55566568600) ;Babovic, I. (14828590600) ;Malvasi, A. (15045047100)Tinelli, A. (15046058900)Purpose: The study aim was to report an unusual case of a misplaced IUD in isthmico-cervical region causing partial uterine perforation and discuss literature data regarding such a condition. Case Report: A 50-year-old women was referred to the present institution for IUD extraction. She was diagnosed with spontaneously misplaced IUD located in isthmico-cervical region of the uterus causing partial perforation. The time of dislocation was unknown, as she was completely asymptomatic for ten years after IUD application. Moreover, she had no risk factors for device misplacement. The removal of IUD was uneventful. Conclusion: Isthmico-cervical misplacement of IUD, although rare, can occur at any time and can be asymptomatic. Thus, women with IUD should be annually checked-up in order to prevent possible IUD complications. - Some of the metrics are blocked by yourconsent settings
Publication Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?(2017) ;Malvasi, A. (15045047100) ;Kosmas, I. (6505812615) ;Mynbaev, O.A. (6602811094) ;Sparic, R. (23487159800) ;Gustapane, S. (37098927400) ;Guido, M. (7005552857)Tinelli, A. (15046058900)Objective. To investigate the effect of trans-resveratrol from Polygonum cuspidatum/magnesium hydroxide complex, trademark Revifast®, plus D-chiro-inositol (DCI) and Myo-inositol (MI) during spontaneous pregnancies in overweight patients in a pilot study. Study design. A one-year, prospective, randomized, doubleblinded, placebo-controlled single center clinical study was carried out on overweight pregnant women. 110 patients were randomized in 3 groups to receive: Revifast® with DCI/MI (group I), DCI/MI alone (group II) or control group (group III) for 30 and 60 days. The main outcomes were to explore the lipid profile (total cholesterol, LDL, HDL, TG) and glucose levels, after 30 and 60 days of therapy. Results. No difference in systolic and diastolic parameters among 3 groups during study. All blood chemistry parameters improved compared to placebo at 30 days already, but significantly to 60 days, respect placebo. By comparing the two treatment groups, group I demonstrates significantly improved lipid and glucose parameters than group II, which are at 30 to 60 days of treatment. Conclusion. The supplementation of Trans-resveratrol, Revifast® in addition to DCI/MI in overweight pregnant woman with an elevated fasting glucose improves glucose levels, Total Cholesterol, LDL and TG. © Società Editrice Universo (SEU).
